Plant Name: Cullen corylifolium
Taxonomic Information:
Plant ID: NPO28809
Plant Latin Name: Cullen corylifolium
Taxonomy Genus: Cullen
Taxonomy Family: Fabaceae
Plant External Links:
NCBI TaxonomyDB:
429560
Plant-of-the-World-Online:
n.a.
Used in Medicines:
Country/Region:
South Korea; IndiaTraditional Medicine System:
Sowa-Rigpa; Indian Folk; Unani; Siddha; Ayurveda; HomeopathyGeographical Distribution:
South Korea; India
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; | |
| FFAR1; FFAR4; | |
| TDP1; BLM; HSD17B10; ALOX15; TNKS; AOX1; | |
| EGFR; | |
| CA2; CA12; CA7; CA4; | |
| PPARA; PPARG; | |
| ESR1; ESR2; | |
| ESRRB; ESRRA; | |
| ALDH2; | |
| LMNA; FABP3; FABP5; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 2 | CYP2A6 | Cytochrome P450 2A6 | P11509 | CHEMBL5282 |
| Cytochrome P450 family 2 | CYP2A13 | Cytochrome P450 2A13 | Q16696 | CHEMBL3542436 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | TNKS | Tankyrase-1 | O95271 | CHEMBL6164 |
| Enzyme_unclassified | AOX1 | Aldehyde oxidase | Q06278 | CHEMBL3257 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 1 group C | PPARG | Peroxisome proliferator-activated receptor gamma | P37231 | CHEMBL235 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Nuclear hormone receptor subfamily 3 group B | ESRRB | Estrogen-related receptor beta | O95718 | CHEMBL3751 |
| Nuclear hormone receptor subfamily 3 group B | ESRRA | Estrogen-related receptor alpha | P11474 | CHEMBL3429 |
| Oxidoreductase | ALDH2 | Aldehyde dehydrogenase | P05091 | CHEMBL1935 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
| Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
| Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 4.660E-10 | 2.029E-06 | BLM, CA12, CA2, CA4, CA7, ESR1, ESR2, ESRRA, ESRRB, PPARA, PPARG, TNKS |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 4.767E-09 | 1.153E-05 | CA12, CA2, CA4, CA7 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 2.078E-08 | 3.480E-05 | CYP1A2, CYP2A13, CYP2A6, CYP2C9 |
| BP | GO:0009987; cellular process | GO:0043401; steroid hormone mediated signaling pathway | 2.761E-08 | 4.294E-05 | ESR1, ESR2, ESRRA, ESRRB, PPARA, PPARG |
| BP | GO:0008152; metabolic process | GO:0006367; transcription initiation from RNA polymerase II promoter | 9.527E-08 | 1.092E-04 | ESR1, ESR2, ESRRA, ESRRB, PPARA, PPARG |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 9.527E-08 | 1.092E-04 | ALOX15, AOX1, CYP1A2, CYP2A13, CYP2A6, CYP2C9 |
| BP | GO:0009987; cellular process | GO:0030522; intracellular receptor signaling pathway | 1.620E-07 | 1.764E-04 | ESR1, ESR2, ESRRA, ESRRB, PPARA, PPARG |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 2.015E-07 | 2.089E-04 | CA12, CA2, CA4, CA7 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 4.606E-07 | 3.679E-04 | CA12, CA2, CA4, CA7 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 5.949E-07 | 4.318E-04 | CYP1A2, CYP2A6, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0008392; arachidonic acid epoxygenase activity | 1.830E-06 | 1.049E-03 | CYP2A13, CYP2A6, CYP2C9 |
| MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 2.026E-06 | 1.103E-03 | ESR1, ESR2 |
| MF | GO:0003824; catalytic activity | GO:0008389; coumarin 7-hydroxylase activity | 2.026E-06 | 1.103E-03 | CYP2A13, CYP2A6 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 6.074E-06 | 2.645E-03 | CA2, CA7 |
| MF | GO:0005488; binding | GO:0005496; steroid binding | 6.911E-06 | 2.849E-03 | ESR1, ESR2, ESRRA, ESRRB |
| MF | GO:0003824; catalytic activity | GO:0016712; oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen | 6.936E-06 | 2.849E-03 | CYP1A2, CYP2A13, CYP2A6 |
| MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 1.214E-05 | 4.404E-03 | ESR1, ESR2 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.214E-05 | 4.404E-03 | CYP1A2, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 1.584E-05 | 5.510E-03 | CYP2A13, CYP2A6, CYP2C9 |
| MF | GO:0005488; binding | GO:0003690; double-stranded DNA binding | 1.594E-05 | 5.510E-03 | EGFR, ESR1, ESR2, ESRRA, ESRRB, PPARA, PPARG, TDP1 |
| BP | GO:0051179; localization | GO:0010891; negative regulation of sequestering of triglyceride | 2.021E-05 | 6.667E-03 | PPARA, PPARG |
| BP | GO:0050896; response to stimulus | GO:0032355; response to estradiol | 2.940E-05 | 8.912E-03 | CYP1A2, EGFR, ESR1, ESRRA |
| BP | GO:0051179; localization | GO:0010887; negative regulation of cholesterol storage | 3.029E-05 | 8.912E-03 | PPARA, PPARG |
| BP | GO:0008152; metabolic process | GO:0010871; negative regulation of receptor biosynthetic process | 3.029E-05 | 8.912E-03 | PPARA, PPARG |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 3.029E-05 | 8.912E-03 | CYP1A2, CYP2C9 |
| MF | GO:0005488; binding | GO:0050543; icosatetraenoic acid binding | 3.029E-05 | 8.912E-03 | FABP3, PPARG |
| MF | GO:0005488; binding | GO:0020037; heme binding | 3.330E-05 | 9.667E-03 | CYP1A2, CYP2A13, CYP2A6, CYP2C9 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 7.221E-09 | 6.788E-07 | CA12, CA2, CA4, CA7 |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 1.962E-06 | 5.864E-05 | CYP2C9, CYP2A6, CYP1A2, AOX1 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 2.495E-06 | 5.864E-05 | CYP2C9, CYP2A6, CYP1A2, AOX1 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 3.129E-06 | 5.883E-05 | CYP2C9, CYP2A6, CYP2A13, CYP1A2 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa03320 | PPAR signaling pathway | 2.495E-06 | 5.864E-05 | FABP3, FABP5, PPARG, PPARA |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 4.985E-06 | 7.811E-05 | CYP2C9, CYP2A6, CYP2A13, CYP1A2 |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 2.345E-05 | 2.449E-04 | ALDH2, CYP1A2, AOX1 |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00280 | Valine, leucine and isoleucine degradation | 4.075E-05 | 3.830E-04 | ALDH2, AOX1, HSD17B10 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 8.763E-06 | 1.177E-04 | CYP2C9, CYP1A2, ALOX15 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 3.523E-04 | 3.010E-03 | ESR1, EGFR, ESR2 |
| Unclassified | Unclassified | hsa01100 | Metabolic pathways | 1.288E-03 | 9.315E-03 | CYP2C9, CYP2A6, ALDH2, CYP1A2, ALOX15, AOX1, HSD17B10 |
| 09150 Organismal Systems | 09155 Excretory system | hsa04964 | Proximal tubule bicarbonate reclamation | 4.696E-04 | 3.678E-03 | CA2, CA4 |
| 09100 Metabolism | 09110 Biosynthesis of other secondary metabolites | hsa00232 | Caffeine metabolism | 1.885E-05 | 2.215E-04 | CYP2A6, CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | ESRRA; FFAR1; |
| K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARG; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ESR1; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | EGFR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1; |
| C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | PPARG; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESR1; ESRRA; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | ESRRA; |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1; |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | EGFR; |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1; |
| C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR; |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | EGFR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | ESRRA; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | EGFR; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| NA: NA | Edema | NA | CA2; |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PPARG; |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1; |
| C00-D49: Neoplasms | Urethral cancer | NA | EGFR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ESRRA; |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | ESRRA; |
| C00-D49: Neoplasms | Cancer | C00-C96 | ESR1; EGFR; |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARG; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | FFAR1; PPARG; |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1; |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9; |
| C00-D49: Neoplasms | Breast cancer | C50 | ESR1; EGFR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | EGFR; |
| C00-D49: Neoplasms | Prostate cancer | C61 | ESR1; EGFR; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | ESR1; |
| C00-D49: Neoplasms | Bladder cancer | C67 | EGFR; |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | EGFR; |
| C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | EGFR; |
| C00-D49: Neoplasms | Melanoma | C43 | EGFR; |
| NA: NA | Menopausal disorder | NA | ESR1; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR; |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | FFAR1; PPARG; |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PPARG; |
| C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR; |
| H00-H59: Diseases of the eye and adnexa | Choroidal neovascularisation | H35 | ESRRA; |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1; |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ALDH2; EGFR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1; |
| C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | EGFR; |
| C00-D49: Neoplasms | Gastric cancer | C16 | EGFR; |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1; |
| NA: NA | Postmenopausal disorder | NA | ESR1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | ALDH2; |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; |
| C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1; EGFR; |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | ESRRA; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | EGFR; |
| C00-D49: Neoplasms | Colon cancer | C50 | EGFR; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PPARG; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | EGFR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1; |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1; |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ESRRA; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR; |
| NA: NA | Gonorrheal vaginitis | NA | ESR1; |
| C00-D49: Neoplasms | Glioma | C71 | EGFR; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | EGFR; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | PPARG; |
| H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | PPARG; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | PPARG; |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | ESRRA; EGFR; |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | EGFR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | ALDH2; |
| A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR; |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | EGFR; |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | ESRRA; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ESRRA; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | PPARG; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; CA2; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
